integration than its larger global competitors Teva TEVA and Mylan MYL . Four major deals for a combined total of $105 billion ..... with Teva, Sandoz (a subsidiary of Novartis NVS), and Mylan . We estimate that these four companies have nearly 50
fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ..... on the right formulation while Mylan has had the generic market to itself. We knew Mylan would eventually face this competition
Mylan ’s reported fourth-quarter results of 18 ..... management’s outlook for the year. We think Mylan ’s narrow economic moat remains intact. Following ..... skeptical of certain products in the pipeline, Mylan ’s ability to launch certain generic products
March 2 (Reuters) - U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week.
March 2 (Reuters) - Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America.
as a smaller player within the generics space, doesn't have the scale to compete with giants such as Teva TEVA and Mylan MYL . The stock's valuation isn't attractive, either, trading well above Krempa's $72 fair value estimate. Royal
changes to our fair value estimate for Mylan even after the company's reported ..... moderately surpassed our expectations. Mylan also benefited from some nonrecurring ..... over quality-control issues during Mylan 's acquisition of that firm's Agila
deteriorating pricing will likely remove some biosimilar threats to Lantus over the long term. We believe both Merck and Mylan will reevaluate launching biosimilars. Nevertheless, Lilly's biosimilar will likely still reach the market in Europe
established pharmaceuticals segment. Now that the branded generics business in mature developed markets is being sold to Mylan , Abbott is set for robust growth focused on the emerging markets. While we do not expect that 13% growth is sustainable
specifically targets "spinversions" makes the Mylan /Abbott subsidiary deal less likely to proceed, hurting Mylan 's valuation. In this case, the valuation of Mylan (not Abbott) would be under pressure, given